MicroQuin

MicroQuin is a biotechnology company founded by Dr. Scott Robinson and Yang Zheng, focused on developing innovative therapeutics to tackle significant health challenges, particularly cancer. The company has created a targeted delivery platform for chemotherapy that selectively directs therapeutic agents to cancer cells while sparing healthy tissues, minimizing toxicity and preserving normal cell function. This approach enhances the efficacy of existing chemotherapeutic drugs in treating various types of cancer, including breast, lung, prostate, ovarian, and melanoma. MicroQuin has gained recognition as a 2018 MassChallenge Finalist and received the CASIS/Boeing Prize to support research aboard the International Space Station. The company is headquartered at LabCentral in Cambridge, Massachusetts.